公开(公告)号：EP4190336A1

公开(公告)日：2023-06-07

申请号：EP21848869.0

申请日：2021-07-30

申请人： Fifth Medical Center of Chinese PLA General Hospital ,  Vcanbio Cell & Gene Engineering Corp., Ltd

发明人： WANG, Fusheng ,  SHI, Lei ,  XU, Ruonan ,  YUAN, Xin ,  ZHANG, Yu ,  YAO, Weiqi

IPC分类号： A61K35/28 ,  A61P11/00 ,  A61P31/14 ,  A61P9/00 ,  A61P31/04 ,  A61P31/10

摘要： Provided is a use of mesenchymal stem cells in the preparation of a drug for repairing lung damage caused by COVID-19. It is proved by clinical tests for the first time that mesenchymal stem cells have an excellent effect on repair of lung damage in subjects with viral pneumonia, especially severe pneumonia caused by SARS-CoV-2 infection, and can significantly reduce solid component lesion volume of the subjects, and repair lung tissue; moreover, it is proved by means of a six minute walking test that mesenchymal stem cells can significantly repair the subjects' cardiopulmonary function, so that the aerobic exercise capacity is significantly improved, thereby effectively alleviating sequelae of the subjects after the end of antiviral treatment, and improving health and quality of life of the subjects; in addition, mesenchymal stem cells are highly safe, and no obvious adverse reactions have been found.

公开(公告)号：EP2570403A4

公开(公告)日：2013-10-09

申请号：EP10851187

申请日：2010-05-14

申请人： CHINESE PLA GENERAL HOSPITAL

发明人： HE KUNLUN ,  LI SONG ,  ZHONG WU ,  LIU JUAN ,  WANG LILI ,  LI XIN ,  HU GUOLIANG ,  LONG LONG ,  XIAO JUNHAI ,  ZHENG ZHIBING ,  LI WEI ,  LI RUIJUN ,  LIU CHUNLEI ,  BAI JIE

IPC分类号： C07C275/24 ,  A61K31/17 ,  A61K31/381 ,  A61K31/425 ,  A61K31/4706 ,  A61P9/00 ,  A61P43/00 ,  C07C275/26 ,  C07C275/28 ,  C07D215/40 ,  C07D275/02 ,  C07D277/02 ,  C07D333/04 ,  C07D333/10

CPC分类号： C07C275/28 ,  C07D215/40

公开(公告)号：EP2589593A1

公开(公告)日：2013-05-08

申请号：EP10851189.0

申请日：2010-05-14

申请人： Chinese PLA General Hospital

发明人： HE, Kunlun ,  LI, Song ,  WANG, Lili ,  LI, Xin ,  ZHONG, Wu ,  HU, Guoliang ,  WANG, Jie ,  LI, Ruijun ,  LIU, Chunlei ,  XIAO, Junhai ,  LONG, Long ,  LI, Wei ,  CHEN, Hua

IPC分类号： C07D215/38 ,  A61K31/47 ,  A61P9/00

CPC分类号： C07D215/40 ,  A61K31/47

摘要： The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis

摘要翻译： 本发明涉及式I的丙烯酰胺化合物或其异构体，药学上可接受的盐和溶剂合物，其涉及包含所述化合物或其异构体，药学上可接受的盐和溶剂合物，以及药学上可接受的载体，赋形剂或稀释剂， 以及该化合物或组合物用于预防和/或治疗与心肌细胞凋亡相关的疾病或病症的用途

公开(公告)号：EP4260826A1

公开(公告)日：2023-10-18

申请号：EP21901983.3

申请日：2021-06-17

申请人： Chinese PLA General Hospital ,  Beijing Chunlizhengda Medical Instruments Co., Ltd

发明人： PENG, Jiang ,  WANG, Zhenguo ,  MENG, Haoye ,  LU, Qiang ,  PAN, Chao ,  WANG, Aiyuan ,  ZHOU, Hao ,  XU, Wenjing ,  LIU, Wei ,  ZHANG, Xingyan ,  SHI, Chunbao ,  CHENG, Xi ,  YUE, Shujun

IPC分类号： A61B17/80 ,  A61L31/02 ,  A61L31/06 ,  A61L31/14

摘要： The present invention discloses a fracture repair device realizing transition from mechanical fixation (association of osteosynthesis, AO) to biological fixation (biological osteosynthesis, BO), including: a bone repair instrument, wherein auxiliary components are arranged at positions, close to a repaired bone surface, of the bone repair instrument, and each auxiliary component is made of a degradable metal material or a composite material thereof or a degradable polymeric material. The device of the present invention only has the advantages of AO rigid mechanical fixation, but also can effectively improve the defects of bone disconnection, fixed segment osteoporosis, re-fracture after defixation, etc., frequently occurring under AO rigid mechanical fixation, realizing transition from mechanical fixation (association of osteosynthesis, AO) to biological fixation (biological osteosynthesis, BO) during bone fixation or repair.

公开(公告)号：EP2573078A4

公开(公告)日：2013-11-20

申请号：EP10851188

申请日：2010-05-14

申请人： CHINESE PLA GENERAL HOSPITAL

发明人： HE KUNLUN ,  LI SONG ,  ZHONG WU ,  LIU JUAN ,  WANG LILI ,  LI XIN ,  HU GUOLIANG ,  WANG JIE ,  LONG LONG ,  XIAO JUNHAI ,  ZHENG ZHIBING ,  LI WEI ,  LI RUIJUN ,  LIU CHUNLEI ,  TANG JIE

IPC分类号： C07D333/04 ,  A61K31/17 ,  A61K31/381 ,  A61K31/435 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61P9/00 ,  A61P43/00 ,  C07C335/12 ,  C07D295/21 ,  C07D333/10 ,  C07D409/12

CPC分类号： A61K31/18 ,  A61K31/17 ,  A61K31/381 ,  A61K31/435 ,  A61K31/4453 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  C07C335/12 ,  C07D295/194 ,  C07D295/21 ,  C07D333/24 ,  C07D409/12

摘要： The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention also relates to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; especially use for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

摘要翻译： 本发明涉及式I化合物或其异构体，药学上可接受的盐和溶剂合物; 本发明还涉及包含式I化合物或其异构体，药学上可接受的盐和溶剂化物以及药学上可接受的载体，赋形剂或稀释剂的组合物。 本发明还涉及式I化合物或其异构体，药学上可接受的盐和溶剂合物在抗凋亡，预防或治疗与细胞凋亡相关的疾病或病症中的用途; 特别用于保护心肌细胞，预防或治疗与心肌细胞凋亡相关的疾病或病症。

公开(公告)号：EP2573078A1

公开(公告)日：2013-03-27

申请号：EP10851188.2

申请日：2010-05-14

申请人： Chinese PLA General Hospital

发明人： HE, Kunlun ,  LI, Song ,  ZHONG, Wu ,  LIU, Juan ,  WANG, Lili ,  LI, Xin ,  HU, Guoliang ,  WANG, Jie ,  LONG, Long ,  XIAO, Junhai ,  ZHENG, Zhibing ,  LI, Wei ,  LI, Ruijun ,  LIU, Chunlei ,  TANG, Jie

IPC分类号： C07D333/04 ,  C07D333/10 ,  C07D409/12 ,  C07D295/21 ,  C07C335/12 ,  A61K31/381 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/435 ,  A61K31/5377 ,  A61K31/17 ,  A61P9/00 ,  A61P43/00

CPC分类号： A61K31/18 ,  A61K31/17 ,  A61K31/381 ,  A61K31/435 ,  A61K31/4453 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  C07C335/12 ,  C07D295/194 ,  C07D295/21 ,  C07D333/24 ,  C07D409/12

摘要： The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention also relates to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; especially use for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

摘要翻译： 本发明涉及式I化合物或其异构体，药学上可接受的盐和溶剂合物; 本发明还涉及包含式I化合物或其异构体，药学上可接受的盐和溶剂化物以及药学上可接受的载体，赋形剂或稀释剂的组合物。 本发明还涉及式I化合物或异构体，其药学上可接受的盐和溶剂合物用于防治凋亡，预防或治疗与细胞凋亡相关的疾病或病症的用途; 特别用于保护心肌细胞，预防或治疗与心肌细胞凋亡相关的疾病或病症。

公开(公告)号：EP0310216A2

公开(公告)日：1989-04-05

申请号：EP88305329.0

申请日：1988-06-10

申请人： CHINESE PLA GENERAL HOSPITAL ,  CITIC TECHNOLOGY INC.

发明人： Wang, Xiangsheng c/o Biomedical Engineering

IPC分类号： A61N1/365 ,  A61B5/04

CPC分类号： A61N1/3621 ,  A61N1/385 ,  A61N1/3943

摘要： Apparatus is described for determining ventricular fibrillation threshold (VFT), as a measure of electro­cardiac stability. Input from ECG electrodes (10) and optionally also a blood pressure sensor (20) are digitised and fed to a data processing unit (50) that controls the operation of a unit (60) for generating specifically coded pulses used to stimulate the heart. The data processing unit (50) adjusts time location and amplitude of the coded pulses relative to a series of pacing pulses, in order to induce anomalous multiple extrasystoles or ventricular tachycardia, the characteristic ECG waveforms being identified by the apparatus and the data processing unit (50) instructing the signal generating unit (60) to stop stimulation without ventricular fibrillation occurring. The data processing unit is set up to calculate VFT using the amplitude of pulse needed to induce ME/VT, and display the calculated VFT value.

摘要翻译： 描述了用于确定心室颤动阈值（VFT）的装置，作为心电稳定性的量度。 从ECG电极（10）和可选地还有血压传感器（20）的输入被数字化并且馈送到数据处理单元（50），该数据处理单元控制用于产生用于刺激心脏的特定编码脉冲的单元（60）的操作。 数据处理单元（50）相对于一系列起搏脉冲来调整编码脉冲的时间位置和振幅，以便引起异常的多个惊厥或室性心动过速，由设备和数据处理单元（ 50）指示信号生成单元（60）停止刺激而不发生心室颤动。 数据处理单元设置为使用诱导ME / VT所需的脉冲幅度来计算VFT，并显示计算出的VFT值。

公开(公告)号：EP3851435A1

公开(公告)日：2021-07-21

申请号：EP19867637.1

申请日：2019-06-05

申请人： Chinese PLA General Hospital ,  Shijiazhuang Sagacity New Drug Development Company, Ltd.

发明人： HE, Kunlun ,  GAO, Xiaojian ,  LIU, Chunlei ,  ZHANG, Zeyu ,  LI, Xin ,  LI, Chen ,  LUO, Yunfu ,  LEI, Maoyi ,  LI, Junmiao ,  WANG, Yiwei

IPC分类号： C07D405/14 ,  C07D471/04 ,  C07D417/14 ,  A61K31/506 ,  C07D491/107 ,  A61P39/00 ,  A61P11/00 ,  A61P9/00 ,  A61P9/12

摘要： The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000m or above.

公开(公告)号：EP3851106A1

公开(公告)日：2021-07-21

申请号：EP19867766.8

申请日：2019-06-05

申请人： Chinese PLA General Hospital ,  Shijiazhuang Sagacity New Drug Development Company, Ltd.

发明人： HE, Kunlun ,  ZHANG, Zeyu ,  GAO, Xiaojian ,  LIU, Chunlei ,  LI, Xin ,  LI, Chen ,  QIAN, Wenyuan ,  YANG, Chundao ,  XU, Guanghai ,  WANG, Yiwei

IPC分类号： A61K31/497 ,  C07D401/14 ,  A61P43/00

摘要： The present disclosure provides application of a compound in conformity with a general formula I, and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating and/or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease or a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000m or above.

公开(公告)号：EP2573078B1

公开(公告)日：2016-11-02

申请号：EP10851188.2

申请日：2010-05-14

申请人： Chinese PLA General Hospital

发明人： HE, Kunlun ,  LI, Song ,  ZHONG, Wu ,  LIU, Juan ,  WANG, Lili ,  LI, Xin ,  HU, Guoliang ,  WANG, Jie ,  LONG, Long ,  XIAO, Junhai ,  ZHENG, Zhibing ,  LI, Wei ,  LI, Ruijun ,  LIU, Chunlei ,  TANG, Jie

IPC分类号： C07D333/04 ,  C07D333/10 ,  C07D409/12 ,  C07D295/21 ,  C07C335/12 ,  A61K31/381 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/435 ,  A61K31/5377 ,  A61K31/17 ,  A61P9/00 ,  A61P43/00

CPC分类号： A61K31/18 ,  A61K31/17 ,  A61K31/381 ,  A61K31/435 ,  A61K31/4453 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  C07C335/12 ,  C07D295/194 ,  C07D295/21 ,  C07D333/24 ,  C07D409/12